Country: Malta
Language: English
Source: Medicines Authority
PRAVASTATIN SODIUM
Aurobindo Pharma (Malta) Limited Vault 14, Level 2, Valletta Waterfront, Floriana FRN 1913, Malta
C10AA03
PRAVASTATIN SODIUM 10 mg
TABLET
PRAVASTATIN SODIUM 10 mg
POM
LIPID MODIFYING AGENTS
Authorised
2012-12-06
Page 1 of 8 PACKAGE LEAFLET: INFORMATION FOR THE USER PRAVASTATIN AUROBINDO 10 MG TABLETS PRAVASTATIN AUROBINDO 20 MG TABLETS PRAVASTATIN AUROBINDO 40 MG TABLETS Pravastatin sodium READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again • If you have any further questions, ask your doctor or pharmacist • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4 WHAT IS IN THIS LEAFLET 1. What Pravastatin Aurobindo is and what it is used for 2. What you need to know before you take Pravastatin Aurobindo 3. How to take Pravastatin Aurobindo 4. Possible side effects 5. How to store Pravastatin Aurobindo 6. Contents of the pack and other information 1. WHAT PRAVASTATIN AUROBINDO IS AND WHAT IT IS USED FOR Pravastatin Aurobindo belongs to a group of medicines called statins (or HMG-CoA reductase inhibitors). It prevents the production of cholesterol by the liver and consequently reduces the levels of cholesterol and other fats (triglycerides) in your body. When there are excessive levels of cholesterol in the blood, the cholesterol accumulates on the walls of blood vessels and blocks them. This condition is called hardening of the arteries or atherosclerosis and it may lead to: • chest pain (angina pectoris), when a blood vessel in the heart is partially blocked, • a heart attack (myocardial infarction), when a blood vessel in the heart is completely blocked, • a stroke (cerebrovascular accident), when a blood vessel in the brain is completely blocked. This medicine is used in 3 situations: In the treatment of high levels of cholesterol and fats in the blood Pravastatin Aurobindo is used to lower high levels of "bad" cholesterol and to raise the levels Read the complete document
Page 1 of 15 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Pravastatin sodium Aurobindo 10 mg tablets Pravastatin sodium Aurobindo 20 mg tablets Pravastatin sodium Aurobindo 40 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg, 20 mg or 40 mg pravastatin sodium. Excipient with known effect: 10 mg: Each tablet contains 67.01 mg lactose monohydrate. 20 mg: Each tablet contains 134.02 mg lactose monohydrate. 40 mg: Each tablet contains 268.05 mg lactose monohydrate. 10 mg: Each tablet contains 0.525mg of sodium. 20 mg: Each tablet contains 1.05mg of sodium. 40 mg: Each tablet contains 2.1mg of sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet 10 mg: Tablet: Yellow, capsule shaped, biconvex, mottled, uncoated tablets with notched sides at double bisect, debossed with a “Y” on one side and “60” on other side. The size is 8.9 mm X 4.5 mm. The tablet can be divided into equal doses. 20 mg: Tablet: Yellow, capsule shaped, biconvex, mottled, uncoated tablets with notched sides at double bisect, debossed with a “Y” on one side and “61” on other side. The size is 11.1 mm X 5.6 mm. The tablet can be divided into equal doses. Page 2 of 15 40 mg: Tablet: Yellow, capsule shaped, biconvex, mottled, uncoated tablets with notched sides at double bisect, debossed with a “Z” on one side and “18” on other side. The size is 14.1 mm X 7 mm. The tablet can be divided into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS HYPERCHOLESTEROLAEMIA Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate. PRIMARY PREVENTION Reduction of cardiovascular mortality and morbidity in patients with moderate or severe hypercholesterolaemia and at high risk of a first cardiovascular event, as an adjunct to diet (see section 5.1). SECONDARY PREVENTION Reduction of cardiovascular mor Read the complete document